skip to Main Content

Maintenance Olaparib Maintains Benefit in Metastatic Pancreatic Cancer, Regardless of Age

Newsfeed image, light gray text on dark gray background
The safety and efficacy of maintenance olaparib (Lynparza) in patients with BRCA1/2-mutated metastatic pancreatic cancer proved to be consistent irrespective of age, according to results of a subgroup analysis from the pivotal phase 3 POLO trial presented during the 2020 ESMO World Congress on Gastrointestinal Cancer.

Results showed that patients within the study who were at least 65 years old and received olaparib as a maintenance therapy were able to obtain long-term progression-free survival (PFS) and a durable tumor response. Read more . . . 

Back To Top